Guidelines & Consensus
US multiple myeloma mortality fell from 1999 to 2024, but inequities persist
Ali et alCancer Causes & Control
A national epidemiological study evaluating multiple myeloma (MM) mortality trends from 1999 to 2024 demonstrated significant overall survival gains alongside persistent demographic and geographic inequities in the United States. Utilizing the CDC Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database, investigators identified MM deaths (ICD-10 code C90.0) and calculated age-adjusted mortality rates (AAMRs) per 1,000,000 using the 2000 U.S. standard population. Temporal patterns were evaluated via joinpoint regression to determine annual percent changes (APCs) and average annual percent changes (AAPCs), and Autoregressive Integrated Moving Average (ARIMA) models were applied to project trajectories through 2034.
Nationally, MM-related AAMRs decreased from 37.6 to 25.1 per 1,000,000 between 1999 and 2024 (AAPC −1.8%; 95% CI −2.1 to −1.5; p < 0.001). Mortality decline accelerated substantially after 2012 (APC −3.2%; p < 0.001), coinciding with the broader clinical integration of novel classes of therapy including proteasome inhibitors, immunomodulatory agents, anti-CD38 monoclonal antibodies, and CAR-T cell platforms. Adults aged 65 and older maintained the greatest overall burden, though their mortality fell from 230 per 1,000,000 in 1999 to 175 per 1,000,000 in 2024.
Despite overall improvements, marked disparities persisted across demographic subgroups. In 2024, AAMRs were notably higher in males compared to females (32.4 vs 19.8 per 1,000,000). Black or African American individuals experienced the highest burden across all racial and ethnic groups, with 2024 mortality rates exceeding double those of White individuals (48.0 vs 23.5 per 1,000,000). Geographically, nonmetropolitan areas and the Southern census region consistently showed higher mortality rates than metropolitan and other regional counterparts. ARIMA forecasting indicates national AAMRs will decline to approximately 20.0 per 1,000,000 (95% CI 17.5–22.5) by 2034; however, sociodemographic and geographic gaps are projected to continue without targeted interventions, including equitable care access, earlier diagnosis, and improved minority representation in clinical trials.
Key Takeaways
- From 1999 to 2024, US age-adjusted mortality rates for multiple myeloma declined from 37.6 to 25.1 per 1,000,000 population (average annual percent change −1.8%; 95% CI −2.1 to −1.5; p < 0.001), with reductions accelerating after 2012 (annual percent change −3.2%; p < 0.001).
- Persistent demographic disparities were observed in 2024, with Black individuals experiencing more than double the mortality rate of White individuals (48.0 vs 23.5 per 1,000,000) and males exhibiting higher mortality than females (32.4 vs 19.8 per 1,000,000).
- ARIMA models project a continued national mortality decrease to 20.0 per 1,000,000 (95% CI 17.5–22.5) by 2034, though racial, regional (Southern US), and nonmetropolitan inequities are projected to persist.
Read the original sourceCancer Causes & Control
